Hsbc Holdings PLC Buys 16,389 Shares of Accuray Incorporated $ARAY

Hsbc Holdings PLC increased its stake in Accuray Incorporated (NASDAQ:ARAY) by 15.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 122,654 shares of the medical equipment provider’s stock after purchasing an additional 16,389 shares during the quarter. Hsbc Holdings PLC owned approximately 0.12% of Accuray worth $221,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ARAY. Barclays PLC grew its stake in Accuray by 7.6% in the 4th quarter. Barclays PLC now owns 226,812 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 15,993 shares in the last quarter. MetLife Investment Management LLC grew its stake in Accuray by 38.3% in the 4th quarter. MetLife Investment Management LLC now owns 48,234 shares of the medical equipment provider’s stock valued at $96,000 after buying an additional 13,370 shares in the last quarter. Northern Trust Corp grew its stake in Accuray by 0.9% in the 4th quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider’s stock valued at $1,603,000 after buying an additional 7,399 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in Accuray in the 4th quarter valued at approximately $35,000. Finally, Bank of America Corp DE grew its stake in Accuray by 102.7% in the 4th quarter. Bank of America Corp DE now owns 146,803 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 74,394 shares in the last quarter. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Accuray Price Performance

Shares of NASDAQ:ARAY opened at $1.51 on Friday. Accuray Incorporated has a 52-week low of $1.14 and a 52-week high of $2.95. The firm has a fifty day moving average of $1.42 and a 200 day moving average of $1.55. The firm has a market capitalization of $170.14 million, a PE ratio of -75.50 and a beta of 1.26. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.92 and a current ratio of 1.65.

Accuray (NASDAQ:ARAY) last announced its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%.The company had revenue of $127.54 million during the quarter, compared to analysts’ expectations of $123.78 million. Accuray has set its FY 2026 guidance at EPS. As a group, research analysts anticipate that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ARAY has been the subject of a number of recent analyst reports. BTIG Research boosted their price target on shares of Accuray from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Wall Street Zen lowered shares of Accuray from a “hold” rating to a “sell” rating in a research report on Saturday, August 30th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Accuray presently has a consensus rating of “Buy” and a consensus price target of $5.00.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.